At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 16 enrolled
Drug / intervention
LY3526318 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Oral Single-Doses of LY3526318 on Cinnamaldehyde-Induced Dermal Blood Flow in Healthy Females
In Brief
A Phase 1 clinical trial evaluating LY3526318 and Placebo for Healthy. Completed, enrolled 16 participants across 1 site.
Detailed Summary
The main purpose of this study is to learn more about how LY3526318 affects blood flow to the skin in healthy women. For each participant, the study will last up to 28 days and Part B will last up to 78 days, including screening and follow-up.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesBelgium
Collaborators--
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
First PostedDec 2019
Enrollment StartDec 2019
Primary CompletionFeb 2020
Study CompletionMar 2020
TodayJul 2026
First PostedDec 3, 2019
Enrollment StartDec 12, 2019
Primary CompletionFeb 28, 2020
Study CompletionMar 6, 2020
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 6.6 years ago
Interventions
LY3526318drug
Administered orally.
Placebodrug
Administered orally.